Cyclacel Pharmaceuticals, Inc.
Cyclacel Expands Phase 2 Sapacitabine Trial in Elderly AML to Include Patients With MDS
Published in Elder Law Weekly, October 1st, 2008
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) announced that it has advanced sapacitabine into Phase 2 development as a second-line treatment for myelodysplastic syndromes (MDS). The MDS study is designed as a protocol amendment expanding the ongoing Phase 2 trial of sapacitabine in elderly patients with acute myeloid leukemia (AML) to include a cohort of patients with MDS. MDS are a group of hematologic cancers in which the bone marrow becomes unable to produce a sufficient number of healthy blood cells. Patients with MDS often progress to AML.
"We have enrolled our first MDS patient under this expanded Phase 2 protocol," said Dr Judy Chiao, M.D., Vice...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Elder Law Weekly
Source: Elder Law Weekly (2008-10-01)
More Articles from Elder Law Weekly
- NewsRx
NewsRx Launches Education Titles; Offers Free Global Warming Publication - Academy of Managed Care Pharmacy
Academy of Managed Care Pharmacy 2008 Educational Conference Is Goin' To Kansas City! - Adaptis
Healthcare Fraud and the Special Investigations Unit - Aggression
Researchers at Cornell University have published new data on aggression - Aging
Scientists at Yale University publish new data on aging - Alzheimer Disease
New findings from Duke University in the area of Alzheimer disease published - More from this issue of Elder Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
